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1. Introduction 
The axon is a highly specialized compartment of neurons. Besides their basic function 
connecting neurons to their targets, axons play key roles in the nervous system. They are 
involved in the transport of several molecules indispensable to neuronal activity, act as 
sensors to guidance cues during development and regeneration, and are essential to 
maintain normal glial cell functions and myelin sheath assembly (Nave & Trap 2008). Recent 
evidence indicates that mRNA and Schwann cells-delivered ribosomes can be found within 
the axoplasm, suggesting that axons may be capable of synthesizing specific proteins (Court 
et al., 2008). However, most axonal structural proteins are synthesized in the neuronal cell 
body and transported along the length of the axon. Interruption of this supply leads to a 
degenerative process known as Wallerian degeneration (WD) in the distal portion of the 
axon (Coleman, 2005). WD is triggered by intrinsic degenerative pathways that are not 
correlated to cellular apoptosis (Finn et al., 2000). Axon degeneration is a final common 
pathway observed not only after a traumatic nerve injury, but also in many 
neurodegenerative disorders (e.g., Parkinson`s and Alzheimer`s diseases) and in 
demyelinating diseases such as multiple sclerosis (Coleman, 2005; Coleman & Freeman, 
2010). Uncovering the mechanisms that trigger and control axon degeneration is extremely 
relevant, as such knowledge may offer novel tools to treat severed or damaged axons as well 
as several neurodegenerative disorders in which WD takes place. In this chapter, we will 
review the basic concepts of WD, with emphasis on the mechanisms that control axon 
degeneration following trauma. Next, we will address the issue whether or not current anti-
degenerative strategies are efficient and can be envisioned to be applied to humans in the 
near future.  
2. Overview of Wallerian degeneration 
WD is classically referred to as a series of degenerative processes triggered in the distal 
portion of axons after a traumatic injury. WD was originally described by Augustus Waller 
in 1850 based on his observations in transected glossopharyngeal and hypoglossal nerves 
(Waller, 1850). Waller observed that, upon transection, the distal nerve stump underwent 
typical morphological alterations which resulted in total nerve fiber fragmentation followed 
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by disintegration. Although Waller`s description of WD was based on studies with 
transected peripheral nerves, the main features of WD are observed after many types of 
insults (crush, transection, chemical and/or toxic) both in the central nervous system (CNS) 
and in the peripheral nervous system (PNS), and are also present in the course of 
neurodegenerative and demyelinating diseases, suggesting a common triggering 
mechanism (Coleman & Perry, 2002).  
Axons respond rapidly to an injury. Just a few hours after lesion, ultra-structural analysis 
reveals swollen axons with their axoplasms filled with an amorphous matrix (Figure 1) 
resulting from the fact that the major cytoskeleton proteins (microtubules and 
neurofilaments) are being degraded by activation of ubiquitin-proteasome system (UPS) 
and calcium-dependent proteases, respectively (to review, see Vargas & Barres, 2007). This 
event is called granular disintegration of the axonal cytoskeleton resulting in complete 
degradation of axonal organelles and proteins and is the main ultra-structural characteristic 
of axons undergoing WD in the PNS. In central nerve fibers, axon disruption may present in 
two distinct patterns of axoplasm degeneration, as based on the ultra-structural aspect of the 
axoplasm (Figure 1) (Narciso et al., 2001). 
 
 
Fig. 1. Ultra-structural images showing different aspects of axon degeneration. Image A 
represents a sciatic nerve transverse ultra-thin section 48 hours after crush injury in 
C57BL/6 mice. Note a normal nerve fiber (white star) next to a fiber showing aspects of 
degeneration with the dissolution of its axoplasmic elements (black star). Images B and C 
show ultra-thin sections of rat optic nerve, 96 hours after crush injury. Note in B one fiber 
undergoing watery degeneration, whereas panel C shows a fiber undergoing dark 
degeneration. Scale bar = 0.3 µm (A) and 1 µm (B and C) 
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With the onset of WD, the axon will progressively deteriorate and the myelin lamellae will 
be disrupted into small fragments known as myelin ovoids (Lubińska, 1977) (Figure 2). To 
date, this criterion is widely used by several groups to study WD in different models (Farah 
et al., 2011; Narciso et al., 2009).  
 
 
Fig. 2. Wallerian degeneration in C57BL/6 sciatic nerve after crush injury. A. Semi-thin 
transverse section (toluidine blue staining) from a normal mouse sciatic nerve. B. Semi-thin 
transverse section from an injured mouse sciatic nerve 96 hours after crush. Note the 
presence of myelin ovoids (arrowheads). Scale bar = 20 µm 
At a later stage of degeneration, myelin and axonal debris will be removed by resident and 
newly-recruited inflammatory cells (monocytes/macrophages) and microglia (in the CNS) 
and by Schwann cells (in PNS). The clearance of debris is crucial to create a favorable 
microenvironment for axon regrowth, since myelin-proteins block axon regeneration by 
inducing growth-cone collapse (Yiu & He, 2006). During WD, there is an important 
inflammatory reaction which is highly regulated by immune cells 
(monocytes/macrophages, T and B lymphocytes, dendritic cells, neutrophils) and by 
resident non-neuronal cells (microglia and astrocytes in the CNS and Schwann cells in the 
PNS) (Hawthorne & Popovich, 2011; Sanders & Jones, 2006). Activation of these cells is 
temporally-orchestrated and triggers the release of several inflammatory molecules that 
may favor axon degeneration or regeneration. Whether an exacerbated or attenuated 
inflammatory reaction would be beneficial or harmful to lesioned nerves is still a matter of 
investigation. Several reports indicate that, in the damaged PNS, inflammation enhances 
axons regeneration by augmenting macrophages recruitment and myelin debris clearance 
(Barrete et al., 2008; Narciso et al., 2009). On the other hand, in the damaged CNS, the 
scenario is not simple: some reports show that recruited macrophages favor axon 
regeneration (Leon et al., 2000; Yin et al., 2006), while other studies show that it can also be 
toxic to neurons (Gensel et al., 2009; Popovich & Longbrake, 2008). These conflicting results 
are currently subject of an intense debate among neuro-immunological researchers and 
represent an important challenge in the field of neurotrauma (for a review, see Crutcher et 
al., 2006).  
Since Waller`s seminal observations, much has been done in the field of WD. Much of this 
knowledge was produced with the development of the electron microscope, which allowed 
researchers to explore in detail the ultra-structural alterations of damaged axons. For a long 
time, much attention was given to the main mechanisms that control neuronal cell body 
death; however, to this date, there are several unsolved questions, many of them related to 
the molecular and cellular pathways that regulate axon destruction, that make this a 
challenging field for neuroscientists. 
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3. Molecular and cellular basis of WD 
The cascade of events that takes place during axonal degeneration follows a very 
coordinated sequence determined by the type of nerve fiber affected (motor or sensory 
neurons, myelinated or unmyelinated fibers), the type and severity of injury, which may 
vary from a slight crush to complete transection, and by consequences such as deficits in 
axonal transport (Coleman, 2005) or demyelination (De Vos et al., 2008; Nave & Trapp, 
2008). All these factors can affect limb function and recovery in different ways and with 
different timeframes. But, independently of how severe was the injury, axonal degeneration 
will occur in a defined fashion. The sequence of steps in axonal degeneration will be 
discussed in this section. In order to understand the process of axonal degeneration in more 
detail, however, we first need to cover some basic concepts on axon structure and function. 
Each neuron has a highly specialized cylinder-like process that ensures the conduction of 
information from the cell body to the nerve terminals (Debanne et al., 2011). This process is 
called “axon” and differs from the other protrusions named “dendrites” in terms of its 
particular structure and function. The axon emerges from the cell body and varies in length 
and thickness depending on the function and region of the body it innervates (Wang et al., 
2008). Another important feature of axon morphology is the presence or not of a myelin 
sheath, made by oligodendrocytes in the CNS and by Schwann cells in the PNS. The axonal 
cylindrical shape is due to the highly organized cytoskeleton components, mainly 
microtubules and neurofilaments, which are longitudinally aligned along axons. These 
cytoskeletal components are also responsible for maintenance of axon thickness and are 
directly implicated in axonal transport of cargoes in association with motor proteins such as 
dynein and kinesins (De Vos et al., 2008; Perrot et al., 2008).  
As previously mentioned, WD is described as the degeneration of axons distal to the point 
of injury (Waller, 1850). Axonal degeneration is triggered by a large Ca2+ influx (George et 
al., 1995; Martinez & Ribeiro, 1998; Schlaepfer, 1971, 1974), attributed to reversal of the 
function of the plasma membrane Na+/Ca2+ exchanger as a consequence of dysfunction of 
the Na+-K+ ATPase (reviewed in LoPachin & Lehning, 1997). This intracellular Ca2+ 
overload is presumed to cause disruption of mitochondrial oxidative phosphorylation, 
excessive formation of free radicals (Anderson et al., 1995; Young et al., 1982) and activation 
of calpains, calcium-activated neutral cysteine proteases that are responsible for 
cytoskeleton breakdown and myelin protein degradation (Martinez & Canavarro, 2000; 
Stokes et al., 1983) (Figure 1). Cytoskeleton disruption leads to failure of axon structural 
integrity and of important intracellular mechanisms such as axonal trafficking of cargoes 
and energy supply (De Vos et al., 2008). Intracellular calcium stores are also involved in 
important cellular changes that boost secondary degeneration (Staal et al., 2010). Another 
intra-axonal degradation mechanism is the activation of the UPS, which has been implicated 
as a common mechanism for selective protein degradation in a variety of biological 
processes including axonal degradation during WD (Zhai et al., 2003). Axon swelling and 
myelin sheath degradation are the next steps in WD. At this stage, it is possible to observe a 
bead-like pattern formation along the degenerating axon, classically known as myelin 
ovoids; this is followed by disconnection and complete degradation of the distal stump 
(Vargas & Barres, 2007) (Figure 2).  
One of the key events in WD is the clearance of axon and myelin debris. Immediately after 
axonal fragmentation and degradation, Schwann cells in the PNS enter continuous cell 
division, degrade their own membrane and phagocyte myelin and axonal debris (Liu et al., 
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1995; Murinson et al., 2005). Besides, macrophage recruitment and infiltration is initiated via 
cytokine and chemokine signalling, enhancing myelin debris clearance and creating an 
appropriated environment for axonal regeneration in the PNS. A different scenario is 
observed in the CNS, where oligodendrocytes undergo apoptosis and are not involved in 
myelin debris phagocytosis and signaling for macrophage help. This results in delayed 
macrophage recruitment, exposure of myelin inhibitory proteins, formation of an astroglial 
scar and secretion of inhibitory molecules such as chondroitin-sulphate proteoglycans which 
result in a hostile microenvironment for axon regeneration (George & Griffin, 1994) and 
establish irreversible loss of function of the target organs. In contrast, microglia, which are 
considered the resident macrophages of the CNS, are activated after an injury by pro-
inflammatory cytokines, among other signals, and undergo several rounds of cell division 
and morphological changes in order to help phagocytosis of dead cells and myelin debris 
(Ferrer et al., 1990; Kreutzberg, 1995). 
An important tool to better understand the steps and mechanisms involved in WD was the 
discovery of the slow Wallerian degeneration mouse (WldS) (Lunn et al., 1989). In these 
mutant mice, the active process of neurodegeneration and synapse breakdown after an 
experimental injury presents a ten-fold delay (Lunn et al., 1989). The chimeric WldS gene 
resulted from a spontaneous mutation in the C57BL/6 mouse strain, causing a tandem 
triplication in the distal region of chromosome 4 (Conforti et al., 2000), and is known to 
protect axons in both CNS and PNS from degeneration induced by injury, neurotoxins and 
neurodegenerative diseases (Wang et al., 2001). The mutation on chromosome 4 comprises a 
stable 85-kb tandem triplication encoding the N-terminal 70 amino acids of the 
multiubiquitination factor Ube4b fused in frame to the nuclear nicotinamide adenine 
dinucleotide (NAD) producing enzyme nicotinamide mononucleotide adenylyltransferase 
(Nmnat1) (Coleman et al., 1998; Mi et al., 2003). Interestingly, some research groups have 
described a significant therapeutic potential for this mutation. The WldS gene can be used to 
confer neuroprotection using delivery methods such as gene therapy (Wang et al., 2001), 
with the advantage of no side or detrimental effects on other non-neuronal cell types 
(Wishart et al., 2009). 
The differences between CNS and PNS, as pointed out here, include important features 
regarding molecular mechanisms in nervous system degeneration. Therapeutic approaches 
such as anti-degenerative strategies must thus be designed and tested according to the 
target region of the nervous system, type of injury and severity. 
4. Anti-degenerative strategies 
The main goal of an anti-degenerative strategy is to halt the progress of neurodegeneration 
in order to rescue neural and non-neural cells from death. Delaying degeneration can also 
represent a useful approach to open a time-window in which to introduce combinations 
treatments, e.g., administration of trophic factors. To achieve its goal, such approach should 
down-regulate genes related to cellular degeneration and up-regulate those related to 
regeneration. However, this scenario is not simple. During WD, innumerous signaling 
pathways are triggered within the neuron´s cell body, axon, synaptic terminals and also in 
glial cells. To make things worse, we still do not know with certainty the identities of the 
main proteins that control WD. Nonetheless, based on results from animal model 
experiments, promising strategies have been proven to be effective in modulating WD 
progression, raising hopes that they may, in the near future, be applied to humans.  
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Importantly, several studies have shown that the mechanisms that activate neuronal cell 
death pathways and axonal degeneration are different from each other. Blocking neuronal 
death does not prevent axonal degeneration, and inhibiting axonal degeneration does not 
necessarily block neuronal death (Beirowsky et al., 2008; Vohra et al., 2010). In an attempt to 
block or decrease tissue damage after neuronal injury, one should simultaneously take into 
consideration the need to inhibit neuronal death, prevent axonal degeneration and, finally, 
stimulate neuronal regeneration.  
4.1 Neuronal survival  
Following a lesion to peripheral nerves, there are molecular and cellular events that occur 
within the axons acutely after injury and that are followed by other alterations in non-
neuronal and neuronal cells. These changes culminate in the activation of signals 
responsible for initiating the regeneration program but also activate neuronal death 
pathways (Chen et al., 2007; Makwana & Raivich, 2005). The interruption of axonal 
transport is one of the first events that take place after injury and its impact on the flow of 
trophic factors, specially the retrograde transport of ciliary neurotrophic factor (CNTF), 
brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) from target areas, 
promotes neuronal death (Koliatsos et al., 1993; Sendtner et al., 1997). On the other hand, 
activation of the signal transducer and activator of transcription 3 (STAT3) and its 
retrograde transport activates genes important for axonal regeneration (Cafferty et al., 2004). 
The main components of the axoplasm, the microtubules and neurofilaments, are degraded 
through the UPS and calpain, respectively (Ehlers, 2004; Zhai et al., 2003), leading to 
disconnection of the neuronal cell bodies to their targets (Makwana & Raivich, 2005).  
Numerous studies have shown the effects of neutrophic factor and neurotrophins (NT) on 
neuronal survival after injury (Arenas & Persson, 1994; Koliatsos et al., 1993; Yan et al., 
1992). Administration of NGF after sciatic nerve transection completely prevented cell loss 
of dorsal root ganglia neurons (Otto et al., 1987). CNTF and BDNF also prevent death of 
motor neurons after axotomy (Koliatsos et al., 1993; Yan et al., 1992). This role in preventing 
neuronal death is important to preserve a certain amount of neuronal cells that can 
potentially regenerate, resulting in better functional recovery (Chen et al., 2007). The 
importance of NT in neuronal survival after injury was first appreciated when researchers 
found that the levels of some NT and neurotrophic factors, and also their receptors, change 
after lesion and this could account for the roles of different NT on neuronal survival and 
regeneration (Funakoshi et al., 1993). Funakoshi and collaborators (1993) demonstrated 
changes in the profile of NT and their receptors at different times after lesion to the sciatic 
nerve. They showed that levels of BDNF mRNA in the neuronal cell body did not change 
after sciatic nerve transection but, in contrast, there was a marked increase in the proximal 
stump. They also found an increase in BDNF mRNA levels at the target, the gastrocnemius 
muscle, two weeks after lesion. In the case of NT-3, mRNA levels decreased in the cell body 
after injury but returned to baseline levels 3 days after, while levels in the sciatic nerve 
dropped within hours after lesion and came back to baseline levels by 2 weeks after the 
injury. For NT-4, there was no change in the levels of mRNA in the cell body, but there was 
a 5 -fold increase in the proximal stump and a strong decrease in the neuronal target; this 
latter event suggests that expression of NT-4 by target organs depends upon neuronal 
stimulation. Concomitant with changes in the expression of NT, the levels of their receptors 
also changed and this occurred specially in the nerve’s proximal stump. All these changes 
are important to support neuronal survival after damage and they imply that these factors 
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are produced by glial cells and targets organs in an attempt to promote neuronal survival, 
regeneration and re-myelination of the growing axons (Chan et al., 2001; Cosgaya et al., 
2002).  
Another strategy that has been used to prevent cell death is the use of apoptotic and necrotic 
blockers with the aim of inhibiting activation of cell death pathways. However, the 
outcomes from these strategies have only impacted on neuronal survival, and not on axonal 
neuroprotection and regeneration. For example, overexpression of Bcl-2, a mitochondrial 
protein that inhibits the intrinsic pathway of caspase activation, enhances retinal ganglion 
cell (RGC) survival after injury, but its effect is only temporary (for a review, see Isenmann 
et al., 2003). Moreover, BCL-2 overexpression results only in histological improvement after 
traumatic brain injury without better behavior outcomes (Tehranian et al., 2006). Calpains 
are also involved in cell death after injury and are implicated in necrotic and apoptotic 
pathways (McKernan et al., 2007; Paquet-Durand et al., 2007). In vitro studies have shown 
that by inhibiting calpain activation it is possible to attenuate apoptosis in RGC after injury 
to the optic nerve (Smith et al., 2011). Although calpain inhibition can affect neuronal 
survival and provide axonal neuroprotection, there is no evidence that its inhibition can 
promote axonal neuroprotection and neuronal survival at the same time, which is another 
indicative that neuronal death and axonal degeneration are triggered and controlled by 
distinct pathways. 
4.2 Axonal neuroprotection 
As mentioned above, one of the first events triggered upon injury is the degradation of 
cytoskeleton proteins by calpains. Several studies have shown positive effects of calpain 
inhibition in different types of lesion and animal models of CNS and PNS disorders, but the 
precise relationship between calpain activation and neuronal death is not fully understood 
(Couto et al., 2004; Kieran & Greensmith, 2004; McKernan et al., 2007). It has been shown 
that use of calpain inhibitors improves the outcomes of muscle function and cell survival 
after PNS injury (Kieran & Greensmith, 2004). Application of a calpain inhibitor in the distal 
target organ improved the rate of cell survival and muscular function 12 weeks after a crush 
lesion of the sciatic nerve (Harding et al., 1996). To test whether calpain inhibition in 
neuronal cell bodies would have an impact on neuronal survival and muscle function, 
Kieran & Greensmith (2004) delivered a calpain inhibitor to the spinal cord after injuring the 
sciatic nerve. Twelve weeks later they observed an improvement in neuronal survival and 
muscle function, suggesting that calpain inhibition plays an important role on both neuronal 
survival and axonal neuroprotection. Couto and collaborators (2004) showed that a calpain 
inhibitor applied to the site of a crush injury had a neuroprotective effect on optic nerve 
fibers 4 days after injury (Figure 3), while Silmara de Lima and collaborators (unpublished 
dada) observed that the delay in axonal degeneration promoted by calpain inhibition had no 
effect on RGC survival 14 days after optic nerve lesion. These results are important since the 
delay in the onset of WD can create a time-window to add other strategies and investigate 
whether different types of combinational treatments can lead to better results. 
Sodium or calcium channel blockers have also been used in anti-degenerative strategies to 
prevent axonal disintegration. Lo and colleagues (2003) demonstrated that neuroprotection 
to spinal cord axons was achieved using a sodium channel blocker in a model of 
experimental allergic encephalomyelitis. Those authors reported that, besides preventing 
axonal degeneration, nerve fibers from animals treated with the sodium channel blocker 
maintained the ability to conduct action potentials. Calcium channel blockers also proved 
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effective in protecting axons from degeneration and improving neuronal survival in models 
of spinal cord and optic nerve injury, with loss of myelin basic protein and alterations in 
spinal cord evoked potentials attenuated in the former case (Winkler et al., 2003), and RGC 
survival increased in the latter (Karim et al., 2006). 
  
 
Fig. 3. Transverse ultrathin section from rat optic nerve. A represents a normal optic nerve. 
B shows a 4 day-injured optic nerve with numerous axons undergoing WD. C shows a 4 day 
post-injury optic nerve treated with calpain inhibitor prior to the lesion and during the 
survival time. Note that there are more intact fibers with preserved axoplasm when 
compared to the image in B. Scale bar = 2 µm 
Another important system involved in WD is the UPS, which has been implicated in many 
biological processes including protein degradation and axonal pathfinding (Campbell & 
Holt, 2001). The involvement of UPS in the early stages of WD was demonstrated in 
explanted superior cervical ganglion neurons by Zhai and collaborators (2003), who showed 
that they could delay axonal degeneration by using a UPS inhibitor. In the same study, they 
showed that by combining UPS and calpain inhibitors there was also a delay in axonal 
degeneration. However, better results were obtained when the UPS inhibitor was used prior 
to the lesion, suggesting that the UPS is involved in the early phase of WD. According to 
Walker and collaborators (2001), microtubule degradation is sufficient to trigger axonal 
degeneration, whereas neurofilament disruption per se does not affect the distribution of 
microtubules and other elements of the axon cytoskeleton. For these reasons, maintaining 
the integrity of axons and improving neuronal survival may be a way to promote a better 
outcome after nerve fiber injury and to accelerate functional recovery. Therefore, the 
combined use of calpain and UPS inhibitors may be a promising approach for testing in 
clinical trials, as inhibitors can be applied peripherally onto neuronal targets. 
Another promising strategy is to prevent or slow down axonal degeneration using 
pharmacological agents. For example, Da Costa et al. (2010) recently showed that intra-
peritoneal injections of 2,4-dinitrophenol (DNP) every 24 hours following injury 
significantly reduced axonal degeneration in a mouse model of sciatic nerve crush injury.  
Besides, expression of amyloid precursor protein (APP) and neuregulin-1 (NRG1) were 
increased in sciatic nerve longitudinal sections after DNP treatment. APP is related to 
neuronal development, growth and survival (reviewed in Gralle & Ferreira, 2007) and 
NRG1 plays important roles in development and neurodegeneration (Falls, 2003) and is 
involved in myelin thickness control (Michailov et al., 2004). DNP is a well-known 
uncoupler of mitochondrial oxidative phosphorylation (Parascandola, 1974). However, at 
low concentrations, insufficient to produce mitochondrial uncoupling, DNP has been shown 
to be a powerful neuroprotective agent against a variety of insults (reviewed in De Felice & 
Ferreira, 2006; De Felice et al., 2007).  
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5. Conclusions and perspectives 
Since Waller’s first experiments and important observations, huge advances have been 
made in terms of imaging technology, molecular biology tools, genomics and chemical 
compound synthesis and screening. All this progress has allowed a detailed view of the 
mechanisms and molecular intimacy of degenerating axons. From accurate freehand 
drawings to live 3D multiphoton microscopy, researchers have unveiled some of the 
mysteries behind the dynamics of morphological changes of injured nerves. However, we 
still face some basic questions regarding axon degeneration: What are the main molecular 
pathways that trigger axon breakdown after injury? Can we manipulate these key molecules 
in order to prevent axon degeneration? Furthermore, although it is possible to precisely 
monitor specific events during degeneration, there are still many open questions about how 
efficient and which is the best anti-degenerative strategy depending on the type of injury, 
lesioned region (PNS or CNS) and how far from the cell bodies were the axons damaged. 
The time between the injury and the beginning of treatment is also a big issue in terms of 
WD progression and is an important factor regarding limb function recovery. The crosstalk 
between basic and clinical research is one of the key points in developing new strategies and 
testing therapeutic hypothesis. Longitudinal screenings on different types of injuries and 
evaluations of therapies that were applied to each single subject may help to create a 
blueprint for a personalized nervous system injury treatment.  
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